Skip to main content

Table 4 Clinical results

From: Effectiveness of deep brain stimulation on refractory aggression in pediatric patients with autism and severe intellectual disability: meta-analytic review

First autor, year

Clinical scales

Clinical outcomes (Pre-Post DBS)

Positive results

Clinical Improvement %

Effect size

Benedetti‐Isaac et al., 2015 [25]

OAS

PTE1:9/1; Pte2:11/0; PTE3: 8/8

2/3

PTE1: 88%, Pt2: 90%, PTE3: 0%

N/A

Benedetti‐Isaac et al., 2021 [24]

OAS

Pre-ME: 17,73 ± 2,18 vs control 6 mos: 9,68 ± 4,02, vs 12 mos: 5,94 ± 2,27, vs 18 mos: 5,1 ± 1,91

18/19

6,12,18 mos: 45.4%, 66,5%, 71,2%

P:0,01; d = 3,78

Benedetti‐Isaac, et al., 2023a [22]

OAS, ADOS-2, WISC-IV

Pre-ME:18,60 ± 2,07 vs 6 mos: 11,80 ± 4,87, vs 12 mos: 6.80 ± 1.32, vs 8 mos: 6.60 ± 3.13

5/5

6, 12, 18 mos: 36,5%, 63,4%, 64,5%

P:0,00; d = 4,81

Benedetti‐Isaac, et al., 2023b [23]

OAS, WISC-IV

Pre-ME: 18.42 ± 3.03 vs 6 mos: 8.92 ± 3.58, vs 12 mos: 5.64 ± 2.00, vs 18 mos: 4.57 ± 0.93

12/12

6, 12, 18 mos: 51,5%, 69,4%, 75.2%

P:0,01; d = 3.75

Escobar Vidarte et al., 2022 [32]

MOAS

27.62 vs 15,57

6/8

42,67%

P:0,02; d = 1.01

Franzini et al., 2013 [12]

OAS, IQ

10 vs 1,5

2/2

85%

N/A

Giordano et al., 2016 [5]

MOAS, CPM

MOAS Pre: 34. Pos: 7 y 11

CPM ME global: 45

1/1

67,7% y 79,5%

-

Harat et al., 2021 [37]

MOAS, BPAQ

PTE1 MOAS 60 vs 1. BPAQ: 117 vs 58

PTE2 MOAS: 11 vs 1. BPAQ: 102 vs 90

1/2

PTE1: 98.3%, 50,4%. PTE2: 90.9%, 11,7%

N/A

Heiden et al., 2022 [39]

ERBI

ERBI Initial: 110; 6-month check-up: 160

1/1

45%

N/A

Kakko et al., 2019 [35]

N/A

N/A

1

N/A

N/A

López Ríos et al., 2022 [33]

MOAS, EQ-5D-5L

MOAS Pre-Post DBS: 40/3

1/1

MOAS: 92,5%

-

Maley et al., 2010 [40]

N/A

N/A

1/1

N/A

N/A

Micieli et al., 2017 [34]

MOAS, QOLS

N/A

4 / 4

N/A

N/A

Park et al., 2017 [36]

GCI-S, GCI-I, ABC, CY-BOCS, K-ARS, SRS

CGI-S: pre: 6; W4: 5; Year2: 4

CGI-I: pre:(No); W1:4; W4: 3; Year2: 2

ABC: pre: 106. W4: 71; Year2: 40. Year2: 7

1/1

CGI-S: W4: 16,6%; Year2: 33,3%

CGI-I: W4: 25%; Year2: 50%

ABC: W4: 33%; Years2: 62,2%

 

Stocco, et al., 2014 [38]

JHMRS

PTE1: Pre-DBS: 30; 13 mos: 0

PTE2: Pre-DBS: 50; 13 mos: 50

1/2

PTE1: 100%; PTE2: 0%

N/A

Sturm et al., 2012 [30]

CGI, ADI-R

CGI (HS: 20/20; CNV: 8/7; CERR: 18/13)

1/1

N/A

N/A

Torres et al., 2013, 2020 [6, 41]

ICAP, DSM-IV GAF, MBI

ICAP: -38,5 ± 5,3 vs -16,3 ± 4,7

1/1

57,14%

N/A

ICAP: -38/-18

52%

N/A

  1. Clinical scales. OAS Overt Aggression Scale, MOAS Modified Overt Aggression Scale, BPAQ Buss-Perry Aggression Questionnaire (Amity version), ERBI Early Rehabilitation Barthel Index, EQ-5D-5L European Quality of Life5 Dimensions, CGI-S The Clinical Global Impression-Severity, GCI-I Clinical Global Impairment-Impression, ABC Antecedent, Behavior, Consequence, JHMRS John’s Hopkins motor stereotypy rating scale, CGI Clinical Global Impression Severity Scale, ICAP Inventory for Client and Agency Planning. CPM Clinical outcomes, Coloured progressive matrices; ADOS-2 Observational Scale for the Diagnosis of Autism, WISC-IV Wechsler Intelligence Scale for Children, ADI-R interview for autism detection, IQ Intelligence Quotient Classification, DSM-IV GAF Global Assessment of Functioning, QOLS The Quality-of-Life Scale, MBI Maladaptive Behavior Index Spanish version (MBI of the ICAP). P t of Student, d effect size, N/A Not available
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us